Sumit Bilgaiyan
Sheela Foam reported very good set of nos. Overall revenue increased 15% YoY on the back of increase in selling price. India revenue was up 15% YoY. Australia Revenue was up 12% YoY. Volume growth stood in the range of 2-3%. We are expecting strong profit growth in the future led by better volumes and margins which will be backed by strong sales volume recovery.
The TDI prices are also expected to cool-off after the new plant in Saudi Arabia is operational. The earnings will get boost from pan India launch of mass market brand ‘Starlite’ and mid-market brand ‘Feather Foam’ and
EBITDA margin recovery led by softening raw material prices.
Key demand drivers for Sheela Foam’s products are rising population, urbanization, rising number of nuclear families, changing lifestyles and rising income levels. Looking at the revenue drivers and company’s ability to generate FCF we are recommending a buy.
Top Heal Care Stocks To Invest In 2019: Midland States Bancorp, Inc. (MSBI)
Advisors’ Opinion:
- [By Logan Wallace]
Midland States Bancorp Inc (NASDAQ:MSBI) Director John M. Schultz sold 2,000 shares of the stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $33.70, for a total transaction of $67,400.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
- [By Joseph Griffin]
News headlines about Midland States Bancorp (NASDAQ:MSBI) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Midland States Bancorp earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news coverage about the financial services provider an impact score of 44.8228508822808 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Midland States Bancorp (MSBI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Heal Care Stocks To Invest In 2019: Smart(SFS)
Advisors’ Opinion:
- [By Lisa Levin]
Losers
Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
Arcadia Biosciences, Inc. (N - [By Joseph Griffin]
ValuEngine lowered shares of Smart & Final Stores (NYSE:SFS) from a sell rating to a strong sell rating in a research report released on Wednesday.
- [By Brian Stoffel]
But over the past five years, the industry has been turned upside down by changes in business models, a focus on delivery, and mass consolidation. While the dust is far from settled, here are 10 of the largest publicly traded grocers you can buy stock in.
Company Market Cap Stores Regions Chains
Amazon (NASDAQ:AMZN) $780 billion 500 USA Whole Foods
Walmart (NYSE:WMT) $250 billion 11,700 Worldwide Walmart
Costco (NASDAQ:COST) $86 billion 750 USA Costco
Kroger (NYSE:KR) $21 billion 2,800 USA Kroger, Roundy’s, Ralph’s, Food 4 Less
Sprouts (NASDAQ: SFM) $3 billion 300 Western and Southern U.S. Sprouts Farmer’s Market
Weis Market (NYSE: WMK) $1.3 billion 200 Mid-Atlantic U.S. Weis Market
SUPERVALU (NYSE: SVU) $630 million 100 Midwestern U.S. Cub Foods, Shopper’s Food, Hornbacher
Ingles Market (NASDAQ: IMKTA) $580 million 200 Southeastern U.S. Ingles Market, Sav-Mor
Smart & Final (NYSE: SFS) $360 million 350 Western U.S. Smart & Final, Cash & Carry
Natural Grocers (NYSE: NGVC) $230 million 150 Western U.S. Natural GrocersData source: Yahoo! Finance, company websites.
- [By Motley Fool Transcribers]
Smart & Final Stores (NYSE:SFS)Q4 2018 Earnings Conference CallMarch 13, 2019, 5:00 p.m. ET
Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:Operator
Top Heal Care Stocks To Invest In 2019: Keryx Biopharmaceuticals, Inc.(KERX)
Advisors’ Opinion:
- [By Maxx Chatsko]
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) dropped nearly 20% last month, according to data from S&P Global Market Intelligence. The pharma company announced second-quarter and first-half 2018 results that included disappointing sales revenue for its only drug, Auryxia. As a result, sales lagged behind consensus estimates despite delivering strong year-over-year growth.
- [By Shane Hupp]
ILLEGAL ACTIVITY WARNING: “Bank of New York Mellon Corp Sells 69,607 Shares of Keryx Biopharmaceuticals (KERX)” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4158332/bank-of-new-york-mellon-corp-sells-69607-shares-of-keryx-biopharmaceuticals-kerx.html.
- [By Shane Hupp]
Keryx Biopharmaceuticals (NASDAQ:KERX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Thursday. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 174.39% from the stock’s current price.
- [By Brian Feroldi]
In response to the companies signing a merger agreement, shares of Akebia Therapeutics (NASDAQ:AKBA) and Keryx Biopharmaceuticals (NASDAQ:KERX) fell 18% and 12%, respectively, as of 10:47 a.m. EDT on Thursday.
- [By Paul Ausick]
Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) traded down about 26% Thursday and posted a new 52-week low of $3.30 after closing Wednesday at $4.48. The stock’s 52-week high is $8.38. Volume totaled about 9 million, roughly nine times the daily average. The company announced a merger this morning with Akebia Therapeutics.
Top Heal Care Stocks To Invest In 2019: Synopsys, Inc.(SNPS)
Advisors’ Opinion:
- [By Chris Lange]
The S&P 500 stock posting the largest daily percentage gain ahead of the close was Synopsys, Inc. (NASDAQ: SNPS) which traded up over 6% at $100.70. The stock’s 52-week range is $77.91 to $101.76. Volume was about 4 million compared to the daily average volume of nearly 1 million.
- [By Joseph Griffin]
Champlain Investment Partners LLC boosted its position in Synopsys, Inc. (NASDAQ:SNPS) by 3.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 686,287 shares of the semiconductor company’s stock after purchasing an additional 25,685 shares during the period. Champlain Investment Partners LLC owned about 0.46% of Synopsys worth $57,127,000 as of its most recent filing with the SEC.
- [By Max Byerly]
Glenmede Trust Co. NA reduced its stake in Synopsys, Inc. (NASDAQ:SNPS) by 52.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 216,557 shares of the semiconductor company’s stock after selling 234,854 shares during the quarter. Glenmede Trust Co. NA owned about 0.15% of Synopsys worth $18,531,000 as of its most recent SEC filing.
Top Heal Care Stocks To Invest In 2019: CarMax Inc(KMX)
Advisors’ Opinion:
- [By Garrett Baldwin]
Investors still remain cautious about ongoing trade tensions between the United States and China. This morning, Chinese media outlets said that the Trump administration had “a symptom of paranoid delusions” when it came to its protectionism. Trump is currently threatening another round of tariffs on up to $200 billion in Chinese goods. With yet another round of tariffs on the way, the United States is close to implementing the most significant trade protectionist policies since the 1930s. Shares of Amazon.com Inc. (Nasdaq: AMZN) are generating a lot of buzz after the Supreme Court said it will allow states to collect more sales tax from online retailers. Shares of Wal-Mart Stores Inc. (NYSE: WMT) and Target Corp. (NYSE: TGT) both ticked higher. Despite the small downturn in AMZN stock, Boris Schlossberg, of BK Asset Management, said Wednesday afternoon that the e-commerce giant could soon been worth more than $2,000 per share before we see another pullback from the Nasdaq. AMZN is up 50% in 2018 and has hit 34 new records so far this year. The U.S. Federal Reserve announced that 35 U.S. banks passed their latest round of stress tests, which are designed to determine if a financial institution has enough money in the event of a serious economic downturn or other event. Expect a lot of chatter today about what this means for firms like Bank of America Corp. (NYSE: BAC), Citigroup Inc. (NYSE: C), JPMorgan Chase & Co. (NYSE: JPM), and Goldman Sachs Group Inc. (NYSE: GS).
Three Stocks to Watch Today: BB, INTC, TSLA
Shares of Intel Corp. (NYSE: INTC) are in focus after the company’s CEO, Brian Krzanich, was forced out of his role after admitting to a “consensual relationship” with an employee. INTC stock clawed back about 1% Friday morning after sliding more than 2.3% during Thursday’s trading session. The downsizing of Tesla Inc. (Nasdaq: TSLA) will continue. The company announced last night that it will shutter 12 solar facilities across nine states. T - [By Daniel Miller]
Carvana’s operations are innovative, but investors need more than that to buy in. And that’s where Carvana must consistently show progress on gross profit per unit (GPU). We know Carvana is going to grow its top line as it enters into a slew of new U.S. markets; in fact, Carvana’s 44 markets at the end of the fourth quarter of 2017 are expected to explode to as many as 84 by the end of 2018. But it also needs to narrow the gap with its competitors on GPU. Let’s use CarMax (NYSE:KMX), a competitor that logged an excellent 2018 first quarter, as an example.
- [By Jon C. Ogg]
According to the Merrill Lynch views on the rise in older car models, this is expected to benefit dealers such as CarMax Inc. (NYSE: KMX) and America’s Car-Mart Inc. (NASDAQ: CRMT), as well as auctioneer KAR Auction Services Inc. (NYSE: KAR).